Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Nephrology · Membranoproliferative Glomerulonephritis

Validation & Orientation: Understanding a Primary MPGN Diagnosis

At a Glance

Primary MPGN is not a single disease, but a pattern of kidney injury caused by an overactive immune system. A kidney biopsy classifies the damage as either IC-MPGN or C3G, allowing doctors to use newly approved complement inhibitors to lower proteinuria and protect kidney function.

Receiving a diagnosis like MPGN (Membranoproliferative Glomerulonephritis) can feel overwhelming. It is a complex name for a complex condition, but understanding a few key facts can help clear the fog. First and most importantly: MPGN is not a single disease. Instead, it is a pattern of injury [1][2]. Think of it like a “scar” or “bruise” on the kidney that doctors see under a microscope. Just as a bruise can be caused by many different things, the MPGN pattern is the kidney’s way of showing it has been damaged by the immune system [3].

The Shift to Modern Naming

In the past, doctors used a numbering system (Type I, II, and III) to describe this kidney damage. However, medical science has moved toward a more precise classification based on what is actually causing the injury [4][2]. This modern system looks at the immunofluorescence (a special staining technique) of your kidney biopsy to see which parts of the immune system are involved [2]:

  • IC-MPGN (Immune Complex-Mediated MPGN): This occurs when both immunoglobulins (antibodies) and complement (immune system proteins) are found in the kidney [4][5].
  • C3G (C3 Glomerulopathy): This occurs when only C3 (a specific complement protein) is found, with little to no antibodies [4][2].

This change is important because it helps your care team target the specific part of your immune system that is overactive [6].

What Does “Primary” Mean?

When your doctor calls your condition primary, it means that after a thorough investigation, they did not find an outside trigger—such as a chronic infection (like Hepatitis C) or another autoimmune disease (like Lupus)—causing the kidney damage [7][8]. In a “Primary” diagnosis, the issue is often rooted in the immune system itself, sometimes due to genetic factors or specific proteins that cause the immune system to stay “turned on” when it should be off [9][10].

Three Stabilizing Facts

If you are feeling a “panic spiral,” hold onto these three facts:

  1. You Have a Map: The move to modern classification (IC-MPGN vs. C3G) means your doctors aren’t just guessing; they are looking at the specific molecular “fingerprint” of your disease to guide your care [6][2].
  2. New Treatments are Arriving: For a long time, treatments for MPGN were limited. Today, we are in a new era of medicine with recently FDA-approved complement inhibitors (like iptacopan and pegcetacoplan) that specifically target the pathways causing the damage [11][12][13].
  3. Proteinuria is a Tool: Your doctors will closely monitor proteinuria (protein in your urine). Lowering this number is a clear, measurable goal that helps protect your kidney function over time [14][13].

Navigating the “Pattern of Injury”

Because MPGN is a pattern, your biopsy is the most important piece of the puzzle. It tells the story of how the glomeruli (the tiny filtering units of your kidney) are being affected [1]. While the path ahead may involve more tests—such as blood work to look for C3 nephritic factors or genetic screening—each test is designed to refine that “pattern” into a clear plan of action [9][10]. Diagnosing the specific driver of the injury is the first step toward managing it effectively [1][15].

Return to Home

Common questions in this guide

What does a 'primary' MPGN diagnosis mean?
A primary diagnosis means your kidney damage is rooted in an overactive immune system itself. It means doctors have thoroughly investigated and ruled out outside triggers like chronic infections or other autoimmune diseases.
Is MPGN a specific disease?
No, MPGN is not a single illness. It is a 'pattern of injury' that pathologists see under a microscope on a kidney biopsy. It shows that your kidney's filtering units have been damaged by the immune system.
What is the difference between IC-MPGN and C3G?
IC-MPGN happens when both antibodies and complement proteins are found in the kidney. C3G means mainly the C3 complement protein is present. Knowing this difference helps your nephrologist target the specific part of your immune system causing the damage.
Why is my doctor closely monitoring protein in my urine?
Measuring protein in your urine, known as proteinuria, is one of the best ways to track kidney damage. Lowering your proteinuria level is a primary treatment goal because it helps protect your long-term kidney function.
Are there new treatments for primary MPGN?
Yes. While options used to be limited, there are new FDA-approved medications called complement inhibitors, such as iptacopan and pegcetacoplan. These drugs specifically target the overactive immune pathways causing your kidney damage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my diagnosis based on a 'pattern of injury' seen on the biopsy?
  2. 2.On my immunofluorescence report, was there more C3 than immunoglobulin, or were they both present?
  3. 3.Does my biopsy result fall under IC-MPGN or C3G?
  4. 4.Have we ruled out all secondary causes, like chronic infections or other autoimmune conditions?
  5. 5.What is my current level of proteinuria, and how will we track it over time?
  6. 6.Am I a candidate for any of the newer, targeted complement-inhibitor treatments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    A case report of recurrent membranoproliferative glomerulonephritis after kidney transplantation due to ventriculoatrial shunt infection.

    Völker LA, Burkert K, Scholten N, et al.

    BMC nephrology 2019; (20(1)):296 doi:10.1186/s12882-019-1472-1.

    PMID: 31382904
  2. 2

    Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations.

    Lafayette RA, Charu V, Glassock RJ

    Advances in therapy 2025; (42(5)):2003-2014 doi:10.1007/s12325-025-03167-x.

    PMID: 40146368
  3. 3

    Membranoproliferative glomerulonephritis in Russian population.

    Dobronravov VA, Smirnov AV

    Terapevticheskii arkhiv 2018; (90(12)):39-47 doi:10.26442/00403660.2018.12.000007.

    PMID: 30701832
  4. 4

    De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?

    Abbas F, El Kossi M, Jin JK, et al.

    World journal of transplantation 2017; (7(6)):285-300 doi:10.5500/wjt.v7.i6.285.

    PMID: 29312858
  5. 5

    To interpret and analyze the changing patterns of histology and direct immunofluorescence findings in membranoproliferative glomerulonephritis.

    Nayak PP, Pradhan P, Pradhan D, et al.

    Indian journal of pathology & microbiology 2024; (67(1)):80-85 doi:10.4103/ijpm.ijpm_1015_22.

    PMID: 38358193
  6. 6

    Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy.

    Benigni A, Daina E, Löffler-Wirth H, et al.

    Kidney international 2026; (109(1)):178-195 doi:10.1016/j.kint.2025.08.035.

    PMID: 41076080
  7. 7

    C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

    Alonso-Titos J, Perea-Ortega L, Sola E, et al.

    BMC nephrology 2018; (19(1)):129 doi:10.1186/s12882-018-0927-0.

    PMID: 29884135
  8. 8

    A Case of Myeloperoxidase Antineutrophil Cytoplasmic Antibody (MPO-ANCA)-Positive Membranoproliferative Glomerulonephritis With Latent Tuberculosis Infection.

    Murakami A, Gotoda H, Nakamoto T, et al.

    Cureus 2024; (16(10)):e72063 doi:10.7759/cureus.72063.

    PMID: 39569301
  9. 9

    FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy.

    Garam N, Cserhalmi M, Prohászka Z, et al.

    Frontiers in immunology 2021; (12()):720183 doi:10.3389/fimmu.2021.720183.

    PMID: 34566977
  10. 10

    Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.

    Holle J, Berenberg-Goßler L, Wu K, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(12)):2289-2298 doi:10.1007/s00467-018-4034-z.

    PMID: 30238151
  11. 11

    Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.

    Filippone EJ, Farber JL

    Frontiers in nephrology 2026; (6()):1747678 doi:10.3389/fneph.2026.1747678.

    PMID: 41767602
  12. 12

    Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

    Fakhouri F, Bomback AS, Ariceta G, et al.

    The New England journal of medicine 2025; (393(22)):2210-2220 doi:10.1056/NEJMoa2501510.

    PMID: 41337715
  13. 13

    Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.

    Bomback AS, Daina E, Remuzzi G, et al.

    Kidney international reports 2025; (10(1)):87-98 doi:10.1016/j.ekir.2024.09.030.

    PMID: 39810766
  14. 14

    Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

    Caravaca-Fontán F, Fakhouri F, Licht C, et al.

    Kidney international reports 2026; (11(2)):103671 doi:10.1016/j.ekir.2025.10.028.

    PMID: 41502799
  15. 15

    Mixed cryoglobulinemic membranoproliferative glomerulonephritis due to monoclonal gammopathy of undetermined significance: A case report.

    Hsu JH, Fang YW, Yang AH, Tsai MH

    Medicine 2018; (97(37)):e12416 doi:10.1097/MD.0000000000012416.

    PMID: 30213019

This page explains primary MPGN diagnosis and pathology terminology for educational purposes only. Your nephrologist is the best source for interpreting your specific biopsy results and medical condition.

Get notified when new evidence is published on Primary membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.